Gilead buys $12 bn Kite to fly into cell therapy

Marco Green
August 31, 2017

About 129,255 shares traded. It has underperformed by 16.70% the S&P500.

Bnp Paribas Arbitrage Sa decreased its stake in Gilead Sciences Inc (GILD) by 51.48% based on its latest 2016Q4 regulatory filing with the SEC. The shares were sold on August 1st for an average price of $108.01.

But the search for safe havens was accompanied by stock picking in Home Depot, which rose 1.2 per cent, and other companies likely to benefit from rebuilding efforts in the region.

Gilead shares rose 0.6 percent to $74.21 at 9:19 a.m. before the US markets opened.

Since March 1, 2017, it had 5 insider buys, and 12 insider sales for $6.87 million activity. It has outperformed by 38.77% the S&P500. The Company's brand trades through approximately 240 stores in 27 countries. Whitnell Co owns 0.1% invested in Gilead Sciences, Inc.

Or, it could also, possibly, leave Gilead's high-flying plans grounded. More interesting news about Gilead Sciences, Inc.

Debenhams Plc (LON:DEB) has 0.00% since August 28, 2016 and is.

These funds have also shifted positions in (KITE). EOG shares are down 0.8% to $83.82 premarket. The Motley Fool owns shares of and recommends Gilead Sciences.

The main Israeli beneficiary of the acquisition is the Pontifax fund, which invested $3.8 million in Kite Pharma at an early stage, but which distributed Kite Pharma shares worth $120 million to its investors. Gilead Sciences has a consensus rating of "Buy" and an average price target of $80.64.

Shares of Kite Pharma (NASDAQ KITE) opened at 178.05 on Monday. Next quarter's EPS is forecasted at $-2.39 and the next full year EPS is anticipated to be $-7.06. The Company's divisions are United Kingdom and worldwide. Kbc Grp Nv stated it has 0.8% of its portfolio in Gilead Sciences, Inc. The insider now directly owns 49,400 shares worth $8,795,670. National Bank & Trust Of Nova Scotia invested 0.03% of its portfolio in Gilead Sciences, Inc.

COPYRIGHT VIOLATION NOTICE: "Baird Financial Group Inc". Highfields Capital Mgmt Lp reported 348,100 shares stake. Therefore 63% are positive.

In reaction to the deal news, which was originally reported by the Wall Street Journal and has since then been confirmed by the companies, shares of Kite Pharma were soaring 28.68 percent to $179. The stock of Gilead Sciences, Inc. H.C. Wainwright maintained it with "Buy" rating and $85 target in Tuesday, February 28 report. Cowen & Co maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Monday, September 21 with "Buy" rating. Jefferies Group LLC increased their target price on Kite Pharma from $101.00 to $121.00 and gave the stock a buy rating in a report on Monday, July 10th.

On June 8, 2017 the stock rating was set at "Buy" according to a BTIG Research report which was a boost from the previous "Neutral" rating. 2,400 shares were sold by Kim Helen Susan, worth $197,088.

Investors sentiment increased to 0.93 in 2016 Q4. Its down 0.17, from 1.26 in 2016Q3. It fall, as 3 investors sold Mattersight Corp shares while 5 reduced holdings. Sandy Spring State Bank holds 1,100 shares or 0.01% of its portfolio. 125,600 are owned by Factory Mutual. S Squared Ltd Liability Corp has 467,927 shares. Pinnacle Assocs invested 0.24% in Amgen, Inc. Old Mutual Glob (Uk) Ltd reported 518,969 shares. Trilogy Global Limited Partnership invested in 380,285 shares or 0.91% of the stock. BidaskClub raised shares of Kite Pharma from a buy rating to a strong-buy rating in a report on Friday, June 9th. Wetherby Asset stated it has 12,514 shares or 0.36% of all its holdings. "We will take some time to look at our own portfolio and see what else we can do". California Employees Retirement System accumulated 35,227 shares. (NASDAQ:GILD) for 2,989 shares.

Other reports by Click Lancashire

Discuss This Article